News

This significant fluctuation in stock price directly reflects the market’s assessment of the preliminary research results. The company is focused on developing innovative therapies for refractory cancers, and the early-stage trial results announced this time have attracted great attention from investors. Drastic price movements usually indicate a market repricing of the outlook for clinical data.

(1) According to shipping data on Tuesday, an ultra-large oil tanker named Idemitsu Maru, flying the Panama flag, is attempting to traverse the Strait of Hormuz. The tanker is managed by Idemitsu Tanker Company, a subsidiary of the Japanese refining group Idemitsu Kosan. Idemitsu Kosan declined to comment on specific vessels.(2) The Strait of Hormuz is a critical chokepoint for global oil transportation, and this attempt to cross the strait coincides with a highly sensitive period in the Middle East. The market is closely monitoring the progress of this event, as any signs of blocked passage could trigger a new round of concerns over crude oil supply.(3) Looking ahead, key areas of focus are whether the tanker can pass through the strait smoothly and whether more tankers will attempt to follow suit. Should there be any obstruction or friction incidents, the risk premium for crude oil could rise further, intensifying volatility pressure in the energy market.

Golden Finance April 28th | Novartis (NVS.US) fell 2.37% in pre-market trading, at $140.77. According to reports, Novartis' first quarter 2026 profit came in lower than analysts' expectations and sales unexpectedly declined, as some of its best-selling drugs faced intense competition from generics. The financial report shows Novartis’ net sales for the first quarter were $13.113 billion, down 1% year-on-year, marking the first year-on-year decline in nearly two years. Core operating profit fell 12% year-on-year to $4.897 billion, missing analysts’ forecasts of $5.18 billion. Core earnings per share stood at $1.99, down 13% year-on-year. (Golden Finance)